

## 主な研究課題・発表代表論文

臨床薬理学講座 Clinical Pharmacology

研究領域 臨床薬理学

教授 北原 隆志 Takashi Kitahara

## 主な研究課題

- ・微量分析および薬物動態解析を用いた薬物療法最適化
- ・薬物障害マーカー探索および臨床応用
- ・リアルワールドデータを用いた医薬品関連有害事象の評価
- ・有害事象関連リスク因子の同定と薬物療法への応用

## 発表代表論文

1. A. Saisy, T. Kitahara et al. Pharmacoeconomic study of biologics for psoriasis treatment based on real-world drug survival. *Dermatol Ther.* 5: e15375, 2022
2. N. Okada et al. Clinical impact of a pharmacist-driven prospective audit with intervention and feedback on the treatment of patients with bloodstream infection. *Antibiotics.* 11: 1144.2, 2022
3. N. Okada et al. Hospital outbreak of extended-spectrum beta-lactamase-producing *Escherichia coli* potentially caused by toilet and bath chair use. *Infect Prev Pract.* 4: 100239, 2022
4. N. Okada et al. First reported case of *Lachnoanaerobaculum gingivalis* bacteremia in an acute myeloid leukemia patient with oral mucositis during high dose chemotherapy. *Anaerobe.* 76: 102610, 2022
5. M. Maeda, T. Kitahara et al. Bibliometric analysis of pharmacist's research on antimicrobial stewardship in Japan: an interrupted time series analysis on the implementation of the certification system for infection control pharmacists. *J Pharm Health Care Sci.* 7: 38, 2021
6. N. Okada et al. Impact of area under the concentration-time curve on the prevalence of vancomycin-induced nephrotoxicity in combination with tazobactam/piperacillin or cefepime: A single-institution retrospective study. *Clin Ther.* 43: 1910-1920.e3, 2021
7. N. Okada et al. Assessment of adherence to post-exposure prophylaxis with oseltamivir in healthcare workers: A retrospective questionnaire-based study. *Biol Pharm Bull.* 44: 869-874, 2021
8. M. Ozaki, T. Kitahara. Evaluation of the antiemetic effect of premedication optimized by pharmaceutical support in cisplatin regimens. *Biol Pharm Bull.* 43: 1735-1741, 2020
9. Y. Kodama, T. Kitahara et al. Development of a DNA vaccine for melanoma metastasis by

- inhalation based on an analysis of transgene expression characteristics of naked pDNA and a ternary complex in mouse lung tissues. *Pharmaceutics*. 12: 540-553, 2020
10. N. Okada et al. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. *Sci Rep*. 10: 13773. 2020
  11. N.Matsunaga, T. Kitahara et al., The influence of light sources on sunitinib measurements with photoisomerization. *Biomedical chromatography* 33: e4407, 2019
  12. N. Okada et al. Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study. *European Journal of Clinical Pharmacology*. 5: 1695-1704, 2019
  13. N. Okada et al. Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database. *Cancer Medicine*, 8: 174-181, 2019
  14. N. Okada et al. Relationship between immune-related adverse events and clinical efficacy in melanoma patients treated with nivolumab: a multicenter retrospective study. *Clin Ther*. 41: 59-67, 2019
  15. Y. Kodama, T. Kitahara et al., Splenic Delivery System of pDNA through Complexes electrostatically Constructed with Protamine and Chondroitin Sulfate. *Biol Pharm Bull*. 41: 342-349. 2018
  16. Y.Kodama, T. Kitahara et al., Gene delivery system of pDNA using the blood glycoprotein fetuin. *Journal of drug targeting*. 26: 604-609, 2018
  17. Y.Kodama, T. Kitahara et al., Methotrexate-Coated Complexes of Plasmid DNA and Polyethylenimine for Gene Delivery. *Biol Pharm Bull*. 41: 1537-1542, 2018
  18. N. Okada et al. Potential usefulness of early potassium supplementation for preventing severe hypokalemia induced by liposomal amphotericin B in hematological patients: a retrospective study., *Clin Ther*. 40: 252-260, 2018